<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00192257</url>
  </required_header>
  <id_info>
    <org_study_id>D153-P515</org_study_id>
    <nct_id>NCT00192257</nct_id>
  </id_info>
  <brief_title>Trial to Compare the Safety, Tolerability and Efficacy of Influenza Virus Vaccine, (CAIV-T) With Influenza Virus in Children With Asthma</brief_title>
  <official_title>A Prospective, Randomized, Open-Label, Controlled Trial to Compare the Safety, Tolerability and Efficacy of Influenza Virus Vaccine, Trivalent, Type A&amp;B, Live, Cold-Adapted (CAIV-T) With Influenza Virus Vaccine, Trivalent, Inactivated (TIV) in Children With Asthma Aged 6 Years to 17 Years</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MedImmune LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Wyeth is now a wholly owned subsidiary of Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>MedImmune LLC</source>
  <brief_summary>
    <textblock>
      - Trial to assess asthma exacerbation through to the end of the study; and to demonstrate
      that the efficacy over one season against culture-confirmed influenza-illness; and finally to
      assess the safety and tolerability of CAIV-T in children with asthma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      - To assess asthma exacerbation, being defined as acute wheezing illness associated with
      hospitalization, unscheduled clinic visits, or new prescriptions from study vaccination
      through to the end of the study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2002</start_date>
  <completion_date>May 2003</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To demostrate that the efficacy over one influenza season against culture-confirmed influenza illness caused by community-acquired subtypes antifenically similar to those contained in the vaccine</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>To demonstrate that the efficacy over one season of a single dose of CAIV-T was not inferior to that of one dose of TIV against culture-confirmed influenza-illness of any subtype</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare the efficacy over a defined surveillance period against asthma exacerbations, asthma medication, clinical visits, hospitalizations, days off school (pharma-ecomonic measures) associated with influenza-like illness</measure>
  </secondary_outcome>
  <enrollment>2229</enrollment>
  <condition>Asthma</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CAIV-T and TIV</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  who are aged at least 6 years to 17 years of age at the time of enrollment;

          -  with a clinical diagnosis of asthma by one of the following criteria:

          -  An International Classification of Diseases, Ninth revision (ICD-9) code 493 AND ≥one
             prescription for asthma medication;

          -  OR ≥one prescription for an inhaled beta-agonist and ≥one prescription for cromolyn;

          -  OR ≥Five prescriptions for any asthma medication (adapted from Kramarz et al,2000 and
             Osborne et al., 1995)1,2;

          -  asthma medication* is being defined as:

          -  inhaled and oral β -agonists

          -  theophyllin

          -  inhaled, oral and injected steroids

          -  other unclassified asthma medication

          -  antibiotics used for treatment of respiratory illness associated with a wheezing
             episode;

          -  at least one asthma medication should have been administered in the last 12 months

          -  who, if female and is post-menarche, has provided a negative pregnancy test prior to
             the study vaccination;

          -  who have provided written informed consent (as appropriate and according to national
             guidelines) and whose parent(s)/legal guardian(s) have provided written informed
             consent after the nature of the study has been explained;

          -  who, along with their parent(s)/legal guardian(s), will be available for duration of
             the trial;

          -  who/whose parent(s)/legal guardian(s), can be reached by study staff for the
             post-vaccination contacts [telephone, clinic or home visit].

        Exclusion Criteria:

          -  who/whose parent(s)/legal guardian(s) are perceived to be unavailable or difficult to
             contact for evaluation or study visits during the study period;

          -  with any serious chronic disease (e.g., with signs of cardiac or renal failure or
             severe malnutrition), including progressive neurological disease;

          -  with Down's syndrome or other known cytogenetic disorders;

          -  with a known or suspected disease of the immune system or those receiving
             immunosuppressive therapy, including systemic corticosteroids of a dose equivalent to
             a total of 20 mg/day or greater of prednisolone or equivalent, for more than 14 days
             duration until 2 weeks after corticosteroids have been discontinued 25;

          -  who received any blood products, including immunoglobulin, in the period from six
             months prior to vaccination through to the conclusion of the study;

          -  for whom there is intent to administer any other investigational vaccine or agent from
             one month prior to enrollment through to the conclusion of the study;

          -  who have an immunosuppressed or an immunocompromised individual living in the same
             household;

          -  who received any influenza vaccine in the 6 months prior to enrollment, or are
             anticipated to receive a non-study influenza vaccine after enrollment;

          -  with a documented history of hypersensitivity to egg or egg protein or any other
             component of the CAIV-T or TIV;

          -  who received aspirin (acetylsalicylic acid) or aspirin-containing products in the two
             weeks prior to enrollment or for which use is anticipated during the study;

          -  with any medical conditions that in the opinion of the investigator might interfere
             with interpretation of the study results;

        Note: Pregnancy in any person who has regular contact with the subject is not a
        contraindication to the enrollment or ongoing participation of the subject in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Walker, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>MedImmune LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Berchem</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>October 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2005</study_first_posted>
  <last_update_submitted>October 2, 2006</last_update_submitted>
  <last_update_submitted_qc>October 2, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 3, 2006</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

